Scientists track immune cells in hepatitis d patients on new drug
NCT ID NCT06504485
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how the immune system fights hepatitis D in people who also have hepatitis B. Researchers will measure special immune cells (T cells) in 192 adults before and after 12 months of treatment with the drug bulevirtide. The goal is to see if these immune responses relate to liver damage and whether the drug changes them.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bulevirtide
What this could lead to
If successful, this could help doctors understand why some patients respond to bulevirtide and others don't, potentially guiding better treatment choices for hepatitis D.
What could go wrong
This is an observational study, not a treatment trial. It is small (192 people) and single-center, so results may not apply to all patients. The findings may not lead to any new treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy.
RECRUITINGMilan, 20122, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••